Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

Activating MYD88 mutations are present in 95% of Waldenström macroglobulinemia (WM) patients, and trigger NF-κB through BTK and IRAK. The BTK inhibitor ibrutinib is active in MYD88-mutated (MYD88(MUT)) WM patients, but shows lower activity in MYD88 wild-type (MYD88(WT)) disease. MYD88(WT) patients a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Hunter, Zachary R., Xu, Lian, Tsakmaklis, Nickolas, Demos, Maria G., Kofides, Amanda, Jimenez, Cristina, Chan, Gloria G., Chen, Jiaji, Liu, Xia, Munshi, Manit, Gustine, Joshua, Meid, Kirsten, Patterson, Christopher J., Yang, Guang, Dubeau, Toni, Samur, Mehmet K., Castillo, Jorge J., Anderson, Kenneth C., Munshi, Nikhil C., Treon, Steven P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234368/
https://ncbi.nlm.nih.gov/pubmed/30401751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018022962
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados